Kaletra (Lopinavir/Ritonavir): Research
- Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy (August 17, 2006)
In XVI International AIDS Conference
- Treating Patients With Lopinavir/Ritonavir Alone Still Risky (August 17, 2006)
In XVI International AIDS Conference
On TheBodyPRO.com
- Acid-Reducing Agents Reduce Atazanavir Drug Levels but Not Lopinavir/Ritonavir Levels (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- During the Third Trimester of Pregnancy Lopinavir/Ritonavir Dose Should Be Increased, Study Finds (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
On TheBodyPRO.com
- Better Adherence With Once-Daily Versus Twice-Daily Lopinavir/Ritonavir: New Tablet Formulation Has Improved GI Tolerability (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Brazil, Abbott Reach Deal to Lower Price on Antiretroviral Drug Kaletra (October 12, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Brazil Again Seeks Negotiations With Abbott to Lower Price on Antiretroviral Drug Kaletra (August 19, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Full Virologic Suppression Can Be Maintained With Lopinavir/Ritonavir Alone; Single-Agent Therapies Worth Further Investigation (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
- Coming Soon: New Lopinavir/Ritonavir (Kaletra) Formulation Allowing for 2-Tablet, Twice-Daily Dosing (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
- Once-Daily Lopinavir/Ritonavir Approved for Treatment-Naive Patients (April 29, 2005)
From U.S. Food and Drug Administration
On TheBodyPRO.com
- Notice of Important New Drug Interactions With Norvir, Kaletra (March 30, 2005)
New interactions noted with fluticasone (a component of Flonase nasal spray) and trazodone (Desyrel, an antidepressant).
From U.S. Food and Drug Administration
On TheBodyPRO.com
- Don't Combine Fosamprenavir and Lopinavir/Ritonavir (February/March 2005)
From TheBodyPRO.com
- Lopinavir/Ritonavir Monotherapy in Treatment-Naive Patients (January 2005)
Part of HIV JournalView's Top 10 Research Reports of 2004.
From TheBodyPRO.com
- Kaletra Monotherapy Controversy: amfAR Publishes Overview (October 26, 2004)
In AIDS Treatment News, from AIDS Treatment News
On TheBodyPRO.com
- Summary of Kaletra (Lopinavir/Ritonavir) Labeling Revisions (October 22, 2004)
Long-term efficacy and safety results from two phase II trials have now been included.
From U.S. Food and Drug Administration
On TheBodyPRO.com
- Hepatitis Testing Important for HIVers Before Taking Kaletra (October 13, 2004)
From aidsmap.com
- Hepatitis/HIV Coinfection Linked to Liver Complications in Kaletra Patients (September 2004)
Abstract of a study that recommends testing HIV-infected patients for HBV and HCV and measuring their baseline ALT values before lopinavir/ritonavir therapy is begun.
In HIV Medicine
- Response to Lopinavir/Ritonavir in HIV-Infected Patients Coinfected With Hepatitis C and/or Hepatitis B (July 12, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
- Drug Development News: Abbott (May/June 2004)
New formulations of lopinavir/ritonavir (Kaletra) and ritonavir are in the works.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- First Case of Potential PI Cross-Resistance Reported After Lopinavir Failure (April 29, 2004)
From aidsmap.com
- Lexiva + Kaletra -- Still a Bad Idea (March/April 2004)
A short review of a study presented at CROI 2004.
In Positively Aware, from Test Positive Aware Network
|
Advertisement
|
Email
Glossary
